Medication info
Posiromet Extended-Release Tablets 10/500 mg (Dapagliflozin, Metformin Hydrochloride)

Posiromet Extended-Release Tablets 10/500 mg (Dapagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceutical Co., Ltd.
Appearance
Pink rectangular extended-release film-coated tablets
Packaging
30 tablets/box [(6 tablets/PTP) x 5]
Approval status
Active

MFDS item code 202300298 · Approved 2023.01.18 · Insurance code 641608050

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience with antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy alone: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medication, the dose may be initiated at the existing doses of dapagliflozin and metformin. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other glucose-lowering agents. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher but less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function tends to decline in elderly patients, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Daewoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

View approved original text

This medication is used as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes by administering a combination of dapagliflozin and metformin. Particularly in patients whose glycemic control is insufficient, it is important to refer to expert guidance on the cardiovascular effects of dapagliflozin if there are cardiovascular diseases or risk factors present. This medication effectively helps with blood sugar control and positively supports diabetes management.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience with antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy alone: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medication, the dose may be initiated at the existing doses of dapagliflozin and metformin. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other glucose-lowering agents. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher but less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function tends to decline in elderly patients, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used in the treatment of type 2 diabetes and contains two components. First, the metformin component helps lower blood sugar, but can rarely cause a serious side effect called lactic acidosis. Lactic acidosis is a dangerous condition resulting from an excessive buildup of lactic acid in the body, with symptoms including muscle pain, shortness of breath, weakness, and abdominal pain. If such symptoms occur, consult a physician immediately. Additionally, caution is needed as this medication may pose a risk of hypoglycemia when used with insulin or sulfonylureas. Hypoglycemia can cause symptoms such as dizziness, trembling, and cold sweats. This medication should not be used in patients with poor kidney function, those who are dehydrated, with serious infections, cardiac dysfunction, pregnant or breastfeeding women, and those with certain genetic disorders. In particular, patients with severely impaired kidney function are at risk if they take this medication. Regular kidney function tests are important before and during treatment to check for abnormalities, and elderly patients or those with reduced fluid volume require closer management. This medication can increase urination, potentially leading to reduced fluid volume or low blood pressure, so patients with low blood pressure or those taking diuretics should exercise caution. During treatment, there may be a higher likelihood of genital and urinary tract infections, and if signs of infection manifest, immediate treatment is required. The metformin component may lower vitamin B12 levels, so regular vitamin B12 testing is recommended during long-term use. The risk of severe side effects may increase if this medication is taken with alcohol, so excessive drinking should be avoided during treatment. Temporary discontinuation of this medication is necessary prior to surgery or imaging tests involving iodine contrast agents, and it should be resumed only after kidney function is confirmed to be normal post-surgery. It is safer for women who are pregnant or may become pregnant, or are breastfeeding to avoid using this medication. Elderly patients are at increased risk for reduced kidney function and decreased fluid volume, thus requiring dose adjustments and regular monitoring. In case of overdose, contact a medical facility immediately for appropriate treatment, and metformin can be removed by dialysis. This medication does not significantly affect driving or operating machinery, but caution is advised as dizziness may occur. Lastly, keep this medication out of the reach of children, and store it in its original container to prevent misuse or quality degradation.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 86 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased serum urea
  • weight loss
  • ketoacidosis
  • urinary sepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 degree Celsius and 30 degrees Celsius. Proper storage will help maintain the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

Pink rectangular extended-release film-coated tablets

Package unit

30 tablets/box [(6 tablets/PTP) x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.